Formation Of Antibodies And Subsequent Prediction Of Clinical Response In Patients With Rheumatoid Arthritis Treated With Four Tnf Blocking Agents
Phase of Trial: Phase IV
Latest Information Update: 03 Jan 2017
At a glance
- Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 03 Mar 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 23 Dec 2014 Planned End Date changed from 1 Feb 2015 to 1 Mar 2015 according to ClinicalTrials.gov record.